Insider filing · AKRO

G. Walmsley Graham bought $9.6M of Akero Therapeutics (AKRO)

Executed Jan 30 2025, disclosed Feb 7 2025, 8 days later, against a two-business-day limit.

Not yet measured: the 21-session window has not closed, or the prices around it are not on record.

GG G. Walmsley Graham Director profile →

G. Walmsley Graham (Director) filed 5 Form 4 reports in the past 24 months (3 purchases, 3 sales, 3 filed past the two-business-day deadline), most often in Olema Pharmaceuticals, Inc. (OLMA). The largest single filing was $9.6M of AKRO (200,000 sh × $48.00, as filed), executed Jan 30 2025. The median gap between execution and disclosure was 5 days.

AKRO AKRO AKRO · 63 filings in 24 months ticker → Insider filings, newest first→ View the original filing at www.sec.gov→